Brief: Tonix Pharmaceuticals Plans To Initiate Prader-Willi Syndrome Phase 2 Trial Of Tnx-2900 In 2026
29/09/2025 12:16
Sept 29 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS PLANS TO INITIATE PRADER-WILLI SYNDROME PHASE 2 TRIAL OF TNX-2900 (INTRANASAL POTENTIATED OXYTOCIN) IN 2026 Source text: ID:nGNXb6CrnB Further company coverage: TNXP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview